Cardiovascular disease after renal transplantation. Cardiovasand they occur at least twice as often as in the backcular disease is a major hazard limiting the life expectancy of ground population [2-6]. renal transplant recipients and the most frequent cause of late Traditional risk factors Predictors for CVD in the general population include Key words: cardiovascular disease, renal transplantation, hyperlipidemia, metabolic risk factors, hyperhomocysteinemia.
In the cyclosporine era, with improving success of allograft loss. Patients with renal disease have usually been transplantation, death with graft function emerged as exposed for both traditional, and for them unique, risk factors the leading cause of graft loss after the first year, and it over a prolonged period of time and may carry the burden of advanced atherosclerotic disease already at the time of transaccounts for the majority of graft losses [3, 5] . Of deaths plantation. The observed survival benefit of transplantation is with a functioning graft, more than half are from ischemic probably from elimination of the numerous uremia-related risk heart disease (IHD) and other vascular diseases [3] . The factors. However, immunosuppressive therapy and the chronic risk of death from IHD was found to be 6.4 times higher lar disease in the general population are present in RTRs and are probably also involved in the progression of renal disease [8] . The underlying renal disease resulting Cardiovascular disease (CVD) is the leading cause of in ESRD is frequently a consequence of a disorder leadmorbidity and mortality both in patients with chronic ing to atherosclerotic vascular disease per se, when renal renal disease and after successful renal transplantation.
disease is part or a consequence of this condition (e.g., The burden of CVD exceeds by far that of the general diabetes, hypertensive nephrosclerosis). In addition, papopulation. Many of the traditional CVD risk factors tients with renal disease have several other abnormalities are operative in renal transplant recipients (RTRs). In that are consequences of renal disease and impaired readdition, several features unique to RTRs deserve spenal function and which, in turn, may contribute to the cific attention. development and progression of CVD. Furthermore, pharmacotherapy after transplantation may exert potential adverse effects on CVD manifestations. So, the preexist-
EPIDEMIOLOGY OF CVD FOLLOWING
ing and, to a various extent, persisting or recurring renal RENAL TRANSPLANTATION failure, proteinuria, ongoing inflammation, infections, In spite of the substantial survival benefit of renal transimmunosuppressive, and other therapy will modify the plantation over long-term dialysis [1], transplant recipieffect of traditional risk factors for CVD. Indeed, recent ents have about four times higher mortality after the studies emphasize that the high incidence of IHD is unfirst year compared with the general population [2]. CVD derestimated by the risk factors identified in the general events represent the single most frequent cause of death population [9] . in RTRs accounting for 35-50% of all-cause mortality,
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or less modifiable by lifestyle changes and pharmacother-azathioprine treatment [20] is caused by an inhibitory effect of azathioprine on lp(a) metabolism [19] . apy. Among the modifiable risk factors, obesity, smoking, hypertension, diabetes, hyperlipidemia, and hyperhomo-Several large studies with long follow-up before the statin era (see below) accounted for independent associ-cysteinemia are best delineated. With better understanding of the pathogenic role of these risk factors and evolu-ation between lipid abnormalities, CVD, and mortality. For example, Kasiske found that hypercholesterolemia tion of potent therapeutic agents with moderate side effects, effective modification of cardiovascular risk fac-correlated with posttransplant vascular disease [21] . In a subsequent study, however, only HDL levels among tors and reduction of CVD morbidity and mortality can be achieved in the general population [10]. This article lipid variables were independently associated with IHD [22] . Still, the risk for major IHD after the first year was will focus on some modifiable risk factors for CVD in renal transplant recipients.
increased twofold for patients with serum cholesterol Ͼ200 mg/dL or triglycerides Ͼ350 mg/dL [9]. Aker found a relative risk of 2.3 for post-transplant CVD associated LIPID AND LIPOPROTEIN ABNORMALITIES with LDL cholesterol Ͼ180 mg/dL [23] . Aakhus reported IN RTRS independent association between IHD and total choles-Renal disease is associated with profound abnormaliterol [7]. Roodnat showed in a retrospective study with ties in lipid and lipoprotein metabolism [11] . In RTRs, over five years of follow-up that serum total cholesterol hyperlipidemia is a well-known feature. Factors with inat one year was a significant independent predictor influence on post-transplant hyperlipidemia include age, fluencing all end points, including patient survival [24] . body weight, pretransplant lipid levels, and, not unex-So far, there is no evidence that lipid lowering reduces pectedly, presence of proteinuria and allograft dysfuncthe burden of CVD in RTRs. Several options are availtion. Immunosuppressive agents, in particular corticosteable for intervention. Tailoring immunosuppression with roids and cyclosporine, are important contributory factors corticosteroid or cyclosporine withdrawal or avoidance and [12] . Elevated total and LDL cholesterol occur in about treatment with HMG-CoA reductase inhibitors (statins) 60% and hypertriglyceridemia in about 35%, whereas will improve lipid abnormalities [12, 16] . Statins are low HDL cholesterol is only present in 15% of RTRs widely used and their effects beyond lowering total and [11]. In prospective studies, the time-dependent changes LDL cholesterol levels nominate them as an attractive in cyclosporine-and prednisolon-treated patients are charalternative. Results of an ongoing, large, controlled fluacterized by an increase in total, LDL, and HDL cholesvastatin trial are awaited. terol while triglycerides remain unchanged [13, 14] . The lipoprotein profile may still become more atherogenic THE DIABETIC TRANSPLANT RECIPIENT with triglyceride-rich small, dense LDL, susceptible for oxidation [12] . Enhanced LDL oxidation is indicated by Diabetes is the most common disease leading to ESRD in all Western countries. Diabetic nephropathy is associ-several studies and, of additional concern, both cyclosporine and tacrolimus have been implicated to increase ated with excess CVD morbidity and mortality at all stages of the disease. Diabetic patients manifest the high-LDL oxidation [15] . Tacrolimus, however, appears to have less negative impact on the lipid pattern [16] . Siro-est mortality rate of any group of ESRD patients. Among patients starting dialysis, diabetics present more often limus, on the other hand, is well known for its propensity to cause hyperlipidemia, in particular hypertriglyc-with clinically diagnosed IHD [25] . Even in asymptotic diabetic transplant candidates, coronary angiography eridemia [17] .
Lipoprotein(a), lp(a), is a risk factor for atheroscle-can reveal coronary artery stenosis Ͼ50% in more than half of them [26] . Importantly, a pathologic coronary rotic vascular disease in the general population. Its specific apoprotein, apo(a), shows structural homology with angiography may predict major adverse cardiovascular events after transplantation [26] . The survival benefit of plasminogen and lp(a) can inhibit fibrinolysis. The size of apo(a) is genetically determined, and elevation of renal transplantation over dialysis is especially valid for diabetic transplant recipients [1]. Therefore, it is advo-lp(a) plasma levels shows an inverse relationship with apo(a) isoform size. Lp(a) is often elevated in patients cated that renal transplantation should be the first therapeutic choice for all suitable diabetic ESRD patients. with renal disease [18] . Cross-sectional studies in RTRs yielded conflicting results, but prospective studies dem-Diabetic RTRs are, however, at further increased CVD risk compared with non-diabetics. For example, Lind-onstrate a decrease in lp(a) levels following transplantation [15, 19] . The decrease in lp(a) depends on apo(a) holm reported a twofold higher risk of death from IHD in diabetic RTRs compared with non-diabetics (25% vs. phenotype, and pretransplant lp(a) levels, and is influenced by allograft function and proteinuria [19] . It is 11.4%) [3] . Arend found a 2.9 relative risk of mortality after the first year in diabetics [2] . Registry data from also advocated that the previously reported elevation of lp(a) in cyclosporine-treated patients compared with the United States account also for more than two-fold
S-80
higher than average risk of death from CVD in diabetic tolerance/diabetes, lipid abnormalities with hypertriglyceridemia and low HDL cholesterol levels, and defect RTRs [5]. Aker reported a 4.3 times increased risk of post-transplant CVD in diabetics. [23] . Aakhus found fibrinolysis have strong correlation with atherosclerotic vascular disease in the general population. Insulin resis-IHD in 24% of diabetics versus 12% of non-diabetics [7] . In Kasiske's study, diabetic RTRs had a more than tance and similar lipid abnormalities are present in renal failure. After transplantation, immunosuppressive ther-threefold increased risk for IHD and for cerebrovascular disease and a 28-fold risk for peripheral vascular disease apy, in particular corticosteroids, may further aggravate these metabolic abnormalities. [22] . The relative risk for IHD associated with diabetes was three-to five-fold increased in a subsequent study Obesity [9] . Importantly, recent reports indicate that simultane-Obesity has long been recognized as a significant risk ous pancreas-kidney transplantation reduces excess morfactor for CVD in the general population, mainly from tality in type 1 diabetic RTRs [27] [28] [29] . In addition, CVD induction of other risk factors such as hypertension, insumortality and left ventricular function will improve after lin resistance, and associated metabolic abnormalities successful pancreas transplantation [29] . Restoring nor- [35] . Few ESRD patients are obese; the pretransplant moglycemia may be the most significant factor for imfrequency is 14-26% depending on definition [32, 23, proved outcomes. 36 ]. Weight gain of more than 10% after transplantation occurs in almost two thirds of patients, is influenced by POST-TRANSPLANT HYPERTENSION demographic factors, and associated with increase in Hypertension is one of the most powerful predictors both serum cholesterol and triglyceride levels [36] . The for CVD in the general population and is frequently prevalence of obesity is between 28% and 48% 1-2 years associated with other CVD risk factors. Patients with after transplantation [23, 32, 36] . Obese RTRs are at inrenal disease have 60-100% prevalence of hypertension creased risk of adverse outcomes. Postoperative complica-[10]. Pretransplant hypertension is a strong predictor of tions are more common, and the risk to develop postpost-transplant hypertension. Several other contributory transplant diabetes mellitus (PTDM) is increased (12% factors are recognized [30] . Genetic factors may also vs. 2%) [37] . Obesity with body mass index (BMI) Ͼ30 have an impact [31] . The prevalence increased from 50% kg/m 2 was also found to be associated with reduced pato 70-90% in the cyclosporine era [30, 32] . Corticostetient survival and increased prevalence of IHD [37] . roids account for 15% of it [33] , and steroid withdrawal Moderate obesity (BMI Ͼ25 kg/m 2 ) was also associated ameliorates hypertension [16] . Tacrolimus and cyclowith a 2-3 fold increased risk of CVD [23] and a twofold sporine seem to have similar adverse impact on blood presincreased risk for graft loss and death [38] . sure in RTRs [16] . Ambulatory blood pressure monitor-Impaired glucose tolerance (IGT) and PTDM ing may reveal a disturbed diurnal variation (non-dipper
The diabetogenic effect of corticosteroid therapy is pattern), which was found to occur in 94.5% of patients well established and is principally mediated by induction with chronic allograft nephropathy [34] . Post-transplant of insulin resistance [39] . Both cyclosporine and tacrolihypertension may be associated with hyperlipidemia, mus have adverse impact on insulin and glucose metabo-IHD, and allograft failure and is also a significant indelism, with tacrolimus possibly being more diabetogenic, pendent risk factor for CVD [7] . especially in certain patient populations [16, 39] . Insulin Treatment of hypertension should be aggressive with resistance and impaired glucose tolerance (IGT) is often target blood pressure below 130/80 [10, 30] . Several studpresent in RTRs [32, 40] . When insulin resistance is assoies have shown that CCBs may protect from cyclosporine ciated with impaired insulin secretion, PTDM will denephrotoxicity [30] . On the other hand, one recent study velop [40] . At 10 weeks after transplantation 52% of found adverse impact on IHD risk of dihydropyridine patients had glucose intolerance, including those with CCBs [9]. Patients with proteinuria would benefit more PTDM [40] . Age, heredity, corticosteroid dose, hypertriby treatment with angiotensin-converting enzyme inhibiglyceridemia, elevated apoB and 2-hour insulin levels tors (ACE-Is) or angiotensin receptor antagonists. ACE-Is were all independently associated with these abnormalimay have additional beneficial effects by reducing postties, thus linking IGT and PTDM to the metabolic syntransplant erythrocytosis. The cardioprotective properdrome [40] . ties of ␤-blockers should be weighed against possible
The frequency of PTDM in the cyclosporine era is adverse metabolic consequences [30] .
8-18%, with manifestation most frequently reported during the first 3 post-transplant months [39] . According METABOLIC RISK FACTOR SYNDROME to a recent report, the risk of PTDM may increase contin-Features of the metabolic risk factor syndrome [35] with uously with time after transplantation, and the prevalence has almost doubled since 1995 (5.9 vs. 10.5% at obesity, hypertension, insulin resistance/impaired glucose 1 yr and 8.8 vs. 16 .9% at 3 yrs) [41] . It is estimated that of CVD and mortality in kidney transplanted smokers steroids are responsible for 10%, and cyclosporine for [2, 23, 48, 49] . Smoking had similar negative impact on an additional 5% [33] . Similar to IGT, older age, higher patient survival as diabetes [48] . Heavy smokers (Ͼ25 steroid doses, and a positive family history of diabetes pack-years) at the time of transplantation had 1.42 relaare established risk factors for PTDM [39] . PTDM is tive risk for post-transplant mortality and 2.14 relative associated with a more than twofold increased relative risk for CVD [49] . There was no adverse effect of smokrisk of IHD, and also with higher post-transplant cholesing among patients who quitted more than 5 years before terol and triglyceride and lower HDL levels, further matransplantation [49] . Smoking cessation is highly recomjor predictors of IHD [22] . The adverse impact of PTDM mended for patients with renal disease. on patient survival is, however, not equally evident at different centers. For example Miles reported 12-year RENAL DISEASE/UREMIA-ASSOCIATED survival of PTDM patients similar to controls (71% vs.
RISK FACTORS 74%) [42] . Revanur found inferior 10-year survival of PTDM patients compared with non-diabetics (49% vs. Homocysteine 75%) [43] . Only patients younger than 55 years ac-Moderate hyperhomocysteinemia is an independent counted for this survival difference, and for them, PTDM predictor of atherosclerotic vascular disease in the genwas associated with 2.54 times higher risk of death [43] . eral population. In renal failure, hyperhomocysteinemia Similar to lipid abnormalities, management of PTDM develops in parallel with the degree of decreasing GFR may include modification of immunosuppression with suc- [50] . After renal transplantation, total homocysteine (tHcy) cessive withdrawal or avoidance of corticosteroids and levels decrease but do not normalize [51] . Whether cyclocalcineurin inhibitors, strategies with well-documented sporine therapy contributes to elevated post-transplant beneficial metabolic consequences [39] . Achievement of tHcy levels is controversial [50-53]. Tacrolimus-treated optimal metabolic control with oral hypoglycemic agents patients were not found to have independent difference and if necessary with insulin therapy, albeit not docuin tHcy levels compared with those treated with cyclomented in RTR, is probably as important as in nonsporine [54] . Association of elevated PAI-1 activity and transplanted diabetic patients [39] .
homocysteine levels is of interest, linking hyperhomocys-Fibrinolysis teinemia to defect fibrinolysis and the metabolic syndrome [55] . Increased tHcy levels are present in 5,10-Impaired fibrinolysis is associated with increased carmethylenetetrahydrofolate reductase (MTHFR) gene diovascular morbidity. PAI-1 is the specific inhibitor of polymorphism (677 C Ͼ T). However, the TT genotype the fibrinolytic system, and elevated levels of PAI-1 are associated with impaired fibrinolysis, increased risk of is not over-represented in RTRs [55]. thrombosis, and CVD in the general population. Ele-Hyperhomocysteinemia is linked to an almost threevated PAI-1 levels are coupled with other features of fold risk of de novo or recurrent CVD in ESRD and sugthe metabolic risk factor syndrome such as obesity, hygested as a risk factor for CVD in RTRs by several studies pertriglyceridemia, and hyperinsulinemia and non-insu- [56] . Recently, tHcy was found to be associated with a lin dependent diabetes, thus linking defective fibrinolysis relative risk of 1.06 for CVD [52] . Notably, s-creatinine to the insulin resistance syndrome. Impaired fibrinolysis levels were also independently related to CVD events and elevated PAI-1 activity are frequently observed in (1.34 relative risk) and were also the major determinants RTRs [32, 44, 45 ]. Both corticosteroids [44] and cycloof tHcy levels. The importance of serum creatinine as sporine [45] are suggested contributors. Hypercholesthe major independent determinant of plasma tHcy level terolemia, obesity, and steroid-induced diabetes could is underlined by a recent study [53] . Two other studies be identified as risk factors for elevated plasma PAI-1 could not find any association between hyperhomocysactivity in cyclosporine-treated patients [45] . Conversion teinemia and patient or graft survival [57, 58] . from cyclosporine to azathioprine as well as steroid with-Folic acid supplementation in pharmacological dose, drawal resulted in improved fibrinolysis and decrease in preferably complemented with B 6 and B 12 vitamins, can PAI-1 levels [46, 47] . Presence of impaired fibrinolysis effectively reduce the hyperhomocysteinemia of RTRs together with all other features of the metabolic syn- [54, 56] . This decrease seems to be influenced by the drome six months after transplantation was associated MTHFR genotype, as patients with the 677TT genotype with poor outcome [32] .
reduce tHcy levels most. Furthermore, elevated PAI-1 levels also decreased after 2 months of therapy [55] . The SMOKING potential beneficial effect of vitamin supplementation on patient and/or graft survival and on CVD events in RTRs Smoking increases the risk for CVD in the general population. Several studies demonstrated increased risk remains to be demonstrated.
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Proteinuria dent risk factor for increased mortality after transplantation in the United States [67] . Proteinuria is a risk factor not only for progressive renal disease but also for CVD [8] . In RTRs, both early and late proteinuria predicts adverse outcome [59, 60] .
SUMMARY Proteinuria one year after transplantation occurred dur-Cardiovascular disease after renal transplantation is ing a follow-up of at least five years associated with a major challenge. As the accelerated atherosclerotic twofold increased risk of death [60] . vascular disease starts during the early phase of chronic renal disease and has a propensity to progress rapidly Left ventricular hypertrophy and dysfunction during dialysis therapy, efforts have to concentrate on LVH is present in the majority of patients starting reducing CVD risk factors at all stages of renal disease. renal replacement therapy and is associated with adverse During the past decade, substantial improvement of paoutcome. Risk hypertension may retard this process [63] . The ACE-DD Umeå, Sweden.
genotype also favors LVH in RTRs, and these patients E-mail: emoke.dimeny@vll.se will, as expected, benefit more from ACE-inhibitors, independent of blood pressure control [64] . Neverthe-REFERENCES less, in a double-blind randomized trial with equally well- 
